Skip to main content
Universal flu vaccine shows promise in small Phase II trial

An experimental broad-acting influenza vaccine elicited an immune response in a trial involving 175 participants, researchers reported in Annals of Internal Medicine, and the results potentially clear the way for a larger trial. The vaccine is designed to target parts of the virus that are not likely to mutate and are found in multiple strains, and its manufacture does not depend on eggs or cell cultures, says Olga Pleguezuelos, chief scientific officer of vaccine developer Seek.

Full Story: